Vanguard Capital Management filed a Schedule 13G with the SEC on October 30, 2026, reporting beneficial ownership of 8,995,805 shares of Palisade Bio Inc common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Vanguard Capital Management reported beneficial ownership of 8,995,805 shares of Palisade Bio Inc common stock.
  • Percent of class: The reported position represents 5.16% of the class of common stock.
  • Sole dispositive power: Vanguard Capital Management holds sole power to dispose of all 8,995,805 shares.
  • Sole voting power: Sole voting power is reported for 1,107,785 shares, with 0 shares subject to shared voting power.
  • Triggering date: The event requiring this filing occurred on September 30, 2026.
  • Type of reporting person: Vanguard Capital Management is classified as an investment adviser (IA) for purposes of this filing.

Vanguard Capital Management's Reported Stake in Palisade Bio Inc

According to the Schedule 13G filed on October 30, 2026, Vanguard Capital Management, headquartered at 100 Vanguard Blvd, Malvern, PA 19355, disclosed beneficial ownership of 8,995,805 shares of common stock in Palisade Bio Inc (NASDAQ:PALI), a company with principal executive offices at 5800 Armada Drive, Suite 210, Carlsbad, CA 92008. The filing was triggered by an event dated September 30, 2026, and the CUSIP number identified for the securities is 696389402.

The filing states that Vanguard Capital Management holds sole dispositive power over all 8,995,805 shares and sole voting power over 1,107,785 shares. Shared voting power and shared dispositive power are each reported as 0. The aggregate position is stated to represent 5.16% of the relevant class. The filing also notes that the reported securities include holdings by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, as well as securities held by clients over which certain affiliates or business divisions exercise dispositive and/or voting power.

The affiliates identified in the filing as part of this reporting group include Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC, and Vanguard Investments Australia Ltd. The filing certifies, per Item 10, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The statement was signed by My Trieu-Gatt, identified as Authorized Signatory, Head of Global Fund Administration.

What Was Disclosed

Vanguard Capital Management filed a Schedule 13G reporting beneficial ownership of 8,995,805 shares, or 5.16%, of Palisade Bio Inc common stock as of September 30, 2026, with sole dispositive power over the full position and sole voting power over 1,107,785 shares.